Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPI | P34949 | 1/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17984942 | 1.00 | MPI (0.43) | MPIAKR1B1LMNAALDH1A1THRB | |
| SCHEMBL4167823 | 1.00 | MPI (0.43) | MPIAKR1B1LMNAALDH1A1THRB | |
| SCHEMBL450548 | 1.00 | MPI (0.43) | MPIAKR1B1LMNAALDH1A1THRB | |
| Phosphoric Acid SCHEMBL5789226 | 0.93 | MPI (0.48) | MPIAKR1B1LMNAALDH1A1 | |
| SCHEMBL15855477 | 0.86 | AKR1B1 (0.39) | MPIAKR1B1LMNAALDH1A1 | |
| Glycerin SCHEMBL9110886 | 0.82 | LMNA (0.47) | MPIAKR1B1LMNAALDH1A1THRB | |
| SCHEMBL17984949 | 0.81 | THRB (0.40) | MPIAKR1B1THRB | |
| SCHEMBL17984951 | 0.80 | AKR1B1 (0.42) | MPIAKR1B1LMNA | |
| SCHEMBL19859338 | 0.79 | MPI (0.34) | MPILMNA | |
| SCHEMBL42624 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110183926-A1 | TREATMENT USING CONTINUOUS LOW DOSE APPLICATION OF SUGAR ANALOGS | UNIVERSITY OF MIAMI (US) | 2011-07-28 | — | — | US | claimed |
| EP-2303282-A2 | TREATMENT USING CONTINUOUS LOW DOSE APPLICATION OF SUGAR ANALOGS | University of Miami (US) | 2011-04-06 | — | — | EP | claimed |
| WO-2009143515-A2 | TREATMENT USING CONTINUOUS LOW DOSE APPLICATION OF SUGAR ANALOGS | UNIVERSITY OF MIAMI (US) | 2009-11-26 | — | — | WO | claimed |
| EP-0582153-B1 | Method of preparing 4-deoxy-D-mannose | JAPAN TOBACCO INC (JP) | 1996-01-17 | — | — | EP | claimed |
| EP-0582153-A1 | Method of preparing 4-deoxy-D-mannose | Japan Tobacco Inc. (JP) | 1994-02-09 | — | — | EP | claimed |
| US-20230242585-A1 | IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-08-03 | — | — | US | disclosed |
| US-10793590-B2 | Antifungal compounds | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2020-10-06 | — | — | US | disclosed |
| US-20190211047-A1 | ANTIFUNGAL COMPOUNDS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2019-07-11 | — | — | US | disclosed |
| US-9994603-B2 | Epimerisation of saccharides | CARGILL, INCORPORATED (US) | 2018-06-12 | — | — | US | disclosed |
| WO-2017210565-A1 | ANTIFUNGAL COMPOUNDS | PRISIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-12-07 | — | — | WO | disclosed |
| CN-106520864-A | Method for enzymatic synthesis of sialic acid analogue and application thereof | 南京农业大学 | 2017-03-22 | — | — | CN | disclosed |
| CN-102883804-B | The epimerization of sugar | 卡吉尔公司 | 2016-10-12 | — | — | CN | disclosed |
| EP-0710501-A2 | Catalyst regeneration | CERESTAR HOLDING BV (NL) | 1996-05-08 | — | — | EP | disclosed |
| EP-0582153-B1 | Method of preparing 4-deoxy-D-mannose | JAPAN TOBACCO INC (JP) | 1996-01-17 | — | — | EP | disclosed |
| EP-0582153-B1 | Method of preparing 4-deoxy-D-mannose | JAPAN TOBACCO INC (JP) | 1996-01-17 | — | — | EP | disclosed |
| EP-0582153-A1 | Method of preparing 4-deoxy-D-mannose | Japan Tobacco Inc. (JP) | 1994-02-09 | — | — | EP | disclosed |
| EP-0582153-A1 | Method of preparing 4-deoxy-D-mannose | Japan Tobacco Inc. (JP) | 1994-02-09 | — | — | EP | disclosed |
| EP-0582153-A1 | Method of preparing 4-deoxy-D-mannose | Japan Tobacco Inc. (JP) | 1994-02-09 | — | — | EP | disclosed |
| EP-0400064-B1 | SOLID CATALYSTS FOR CONTINUOUS INTERCONVERSION OF EPIMERIC ALDOSES AND ALDOSE ANALOGS | UOP (US) | 1993-04-21 | — | — | EP | disclosed |
| US-4815445-A | ANION EXCHANGE RESIN | ALLIED-SIGNAL INC. (US) | 1989-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242585-A1 | IMMUNOMODULATORS | CD274, PDCD1, PDCD1LG2 | MPI 1619/4885AKR1B1 4582/4885LMNA 4649/4885 |
| US-10793590-B2 | Antifungal compounds | DPM1, NACA, SUCLG1 | MPI 725/4885AKR1B1 531/4885LMNA 1413/4885 |
| US-20190211047-A1 | ANTIFUNGAL COMPOUNDS | DPM1, NACA, SUCLG1 | MPI 725/4885AKR1B1 531/4885LMNA 1413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.